192 related articles for article (PubMed ID: 589601)
21. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
22. Kinase and deaminase activity in a variety of subcutaneous mouse tumors.
Furner RL; Mellett LB
Cancer Res; 1975 Jul; 35(7):1799-803. PubMed ID: 165884
[TBL] [Abstract][Full Text] [Related]
23. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells.
Jekunen A; Vilpo JA
J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484
[TBL] [Abstract][Full Text] [Related]
24. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
26. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
Momparler RL; Eliopoulos N; Bovenzi V; Létourneau S; Greenbaum M; Cournoyer D
Cancer Gene Ther; 1996; 3(5):331-8. PubMed ID: 8894252
[TBL] [Abstract][Full Text] [Related]
27. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
Xiang TX; Niemi R; Bummer P; Anderson BD
J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
[TBL] [Abstract][Full Text] [Related]
28. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Eliopoulos N; Cournoyer D; Momparler RL
Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
[TBL] [Abstract][Full Text] [Related]
29. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
White JC; Hines LH
Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
[TBL] [Abstract][Full Text] [Related]
30. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
31. Physiologic disposition of cytosine arabinoside and its derivatives in man.
Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine and cytosine arabinoside in the treatment of murine brain tumor.
Basler GA; Shapiro WR
Cancer Treat Rep; 1976 Jul; 60(7):875-9. PubMed ID: 64295
[TBL] [Abstract][Full Text] [Related]
33. Distribution of [3H]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine.
Dareer SM; Mulligan LT; White V; Tillery K; Mellett LB; Hill DL
Cancer Treat Rep; 1977; 61(3):395-407. PubMed ID: 406044
[No Abstract] [Full Text] [Related]
34. Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907).
Furner RL; Mellett LB
Cancer Chemother Rep; 1975; 59(4):717-20. PubMed ID: 809135
[TBL] [Abstract][Full Text] [Related]
35. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
36. Identification of cytidine deaminase as inhibitor of granulocyte-macrophage colony formation.
Bøyum A; Løvhaug D; Seeberg E; Nordlie EM
Exp Hematol; 1994 Feb; 22(2):208-14. PubMed ID: 7507861
[TBL] [Abstract][Full Text] [Related]
37. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
38. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells.
Mejer JN; Mortensen BT; Christensen IJ
Med Oncol Tumor Pharmacother; 1990; 7(1):25-9. PubMed ID: 2338846
[TBL] [Abstract][Full Text] [Related]
39. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]